Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer

Journal of the National Cancer Institute

Volumn 86, Issue 1, 1994, Pages 18-24

  Kohn, Elise C ^a   Sarosy, Gisele ^a   Bicher, Annette ^a   Link, Charles ^a   Christian, Michaele ^a   Steinberg, Seth M ^a   Rothenberg, Mace ^a   Adamo, Debra Orvis ^a   Davis, Patricia ^a   Ognibene, Frederick P ^b   Cunnion, Robert E ^b   Reed, Eddie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM;

ADULT; AGED; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; FEMALE; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LAPAROSCOPY; MAJOR CLINICAL STUDY; MICROTUBULE ASSEMBLY; MUCOSA INFLAMMATION; NEUROPATHY; OVARY CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SENSORY NEUROPATHY; TUMOR VOLUME;

ADULT; AGED; BONE MARROW DISEASES; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMAN; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0028078681     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.1.18     Document Type: Article

References (30)

1. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by laxol. Nature 277 655-667, 1979
2. Kumar N: Taxol-induced polymerization of purified tubulin. Mecha- nism of action. J Biol Chem 256:10435-10441, 1981
3. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990
4. Chabner BA Taxol Principles & Practice of Oncology Update, vol 5 (9). Philadelphia: Lippincott, 1991, pp 1-10
5. Brown T, Havlm K. Weiss G, et al: A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9:1261-1267. 1991
6. Kris MG, O'Connell JP, Gralla RJ, et al: Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70.605-607, 1986
7. Wiemik PH, Schwartz EL, Einzig A, et al: Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5:1232-1239. 1987
8. McGuire WP. Rowinsky EK, Rosenshein NB, et al: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
9. Sarosy G, Kohn E, Stone DA, et al: Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170. 1992
10. Einzig AL Wiemik PH, Schwartz EL' Taxol: a new agent active in melanoma and ovarian cancer. Cancer Treat Res 58:89-100, 1991
11. Holmes FA, Walters RS, Theriault RL. et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
12. Legha SS, Ring S, Papadopoulos N, et al: A phase II trial of taxol in metastatic melanoma. Cancer 65 2478-2481. 1990
13. Rowinsky EK, Burke PJ, Karp JE, et al: Phase I and phar- macodynamic study of taxol in refractory acute leukemias. Cancer Res 49:4640-4647. 1989
14. Thigpen T, Blessing J, Ball H. et al: Phase II trial of taxol as second- line therapy for ovarian cancer. Proc ASCO 9:156. 1990
15. Einzig AL Gorowski E, Sasloff J. et al: Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 9:133-136, 1991
16. Gabrilove JL, Jakubowski A, Sher H. et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
17. Weiss RB. Donehower RC. Wiemik PH. et al: Hypersensitivity reactions from taxol. J Clin Oncol 8:1263-1268. 1990
18. Rowinsky EK, McGuire WP, Guamieri T. et al: Cardiac disturbances during the administration of taxol J Clin Oncol 9:1704-1712. 1991
19. Markman M. Reichman B, Hakes T, et al Responses to second-line cisplatin-based mtrapentoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805, 1991
20. Bicher A. Kohn E, Sarosy G. et al: The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor. Anticancer Drugs 4:141-148, 1993
21. Buller RE, Berman ML, Bloss JD. et al: CA125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol 165:360-367. 1991
22. Ozols RF. Hamilton TC, Hoskins WJ, et al: Summary of symposium- biology and therapy of ovarian cancer. Semin Oncol 18:297-306. 1991
23. Swenerton K, Eisenhauer E. ten Bokkel Huinink W, et al: Taxol in relapsed ovarian cancer: high vs. low dose and short vs. long infusions. Proc ASCO 12:256, 1993
24. Kavanagh JJ, Kudelka AP, Edwards CL, et al: A randomized cross- over trial of parenteral hydroxyurea vs. high dose taxol in cisplatin/carboplatin resistant epithelial ovarian cancer. Proc ASCO 12:259, 1993
25. Omura GA, Brady MF, Homesley HD. et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150. 1991
26. Lund G, Williamson P, van Houwelingen HC, et al: Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian cancer. Cancer Res 50:4626-4629, 1990
27. Bicher A. Sarosy G, Kohn E. et al: Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 71:594-600, 1993
28. Malkasian G.D. Jr, Melton LJ III, O’Bnen PC, et al: Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 149:274-284, 1984
29. Reed E. Cooper MR, LaRocca RV. et al: Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer 28A:864-866, 1992
30. Reed E, Jacob J, Ozols RF, et al: 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma. Gynecol Oncol 46:326-329, 1992